Circulating microRNA as diagnostic biomarkers for haematological cancers: a systematic review and meta-analysis
- PMID: 31190996
- PMCID: PMC6520596
- DOI: 10.2147/CMAR.S199126
Circulating microRNA as diagnostic biomarkers for haematological cancers: a systematic review and meta-analysis
Abstract
Purpose: Recent studies have validated microRNAs (miRNAs) as a diagnostic biomarker for haematological cancers. This study aimed to estimate the overall diagnostic accuracy of circulating miRNAs in haematological malignancies. Materials and Methods: Multiple databases (Google Scholar, PubMed, EMBASE, Cochrane Library,) were searched until 19th August 2017. Results: The meta-analysis included 50 studies from 20 publications. The diagnostic accuracy was assessed by pooled specificity, sensitivity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the curve area (AUC) by random effect model. We used QUADAS (Quality Assessment for diagnostic accuracy studies) to evaluate the quality of the included studies. To perform the meta-analysis, we used Meta-Disk 1.4, Revman 5.3 and Stata 12.0 software. High diagnostic accuracy was demonstrated, with a sensitivity of 0.81, a specificity of 0.85, a PLR of 5.28, an NLR of 0.22, a DOR of 30.39, and an AUC of 0.91. Subgroup analyses showed better outcomes for the African population, combined miRNAs and leukaemia patients compared with other subgroups. Conclusion: Our results indicated that circulating miRNAs especially combined miRNA can be used as a diagnostic marker in haematological cancers.
Keywords: Specificity; diagnostic biomarkers; haematological cancers; miRNA; sensitivity.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures
References
-
- Slater DN. The new World Health Organization classification of haematopoietic and lymphoid tumours: A dermatopathological perspective. Br J Dermatol. 2002;147:633–639. - PubMed
LinkOut - more resources
Full Text Sources
